View clinical trials related to C-Reactive Protein.
Filter by:The goal of this clinical trial is to compare low-dose colchicine (0.5 mg Once Daily) with no specific intervention in selected elderly patients (60-80 years old) with residual inflammatory risk (hs-CRPâ„ 2mg/L) and multivessel coronary artery disease. The main questions it aims to answer are: - Whether the intervention is effective in reducing ischemic events - Whether the intervention is effective in reducing inflammatory biomarkers' level - Whether the intervention is safe for elderly patients Participants will be randomized to receive low-dose colchicine (0.5 mg Once Daily) or no specific intervention for one year. Patients enrolled should complete one-year follow-up in the form of clinic visit or telephone call.
Infections pose a serious threat to cancer patients in chemotherapy. Prompt diagnosis and treatment is of paramount importance as infections may be life-threatening in immune-compromised individuals. Traditionally, the C-reactive protein (CRP) has been used as a marker of infection. However, the CRP is also often elevated in cancer patients and as a marker CRP may be unreliable in cancer patients. Other markers for infection includes procalcitonin which has been showed to be of some value for the diagnose of bacterial infections. This study examines procalcitonin as a potential marker of bacterial infection in cancer patients.
In the era of emerging antibiotics resistant microbiology, we look for better outcome in the treatment of infections in the elderly. We look for guidelines to manage an elderly who has a permanent urinary catheter, admitting to E.R. with Fever/Sepsis. We assume that exchanging the permanent urinary catheter prior to the Urine Culture sample as well as for initiating antibiotic treatment will improve the outcome of the patients.It could help the day-to-day fight for the proper antibiotics treatment to avoid resistance.